Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 3
2011 4
2012 10
2013 4
2014 7
2015 10
2016 13
2017 12
2018 10
2019 10
2020 11
2021 14
2022 12
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
Katsumata S, Shimokawa M, Hamada A, Haratake N, Nomura K, Fujino K, Yoshikawa M, Suzawa K, Shien K, Suda K, Ohara S, Fukuda S, Kinoshita F, Hayasaka K, Notsuda H, Takamori S, Muto S, Takanashi Y, Mizuno K, Kawase A, Hayakawa T, Sekihara K, Toda M, Matsuo S, Takegahara K, Hashimoto M, Nakahashi K, Endo M, Ozawa H, Fujikawa R, Tomioka Y, Namba K, Matsubara T, Suzuki J, Watanabe H, Takada K, Hoshino H, Kaiho T, Toyoda T, Kouki Y, Shiono S, Soh J, Ohde Y. Katsumata S, et al. Among authors: suda k. Eur J Cancer. 2024 Apr;201:113951. doi: 10.1016/j.ejca.2024.113951. Epub 2024 Feb 22. Eur J Cancer. 2024. PMID: 38417299
Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and EGFR exon 20 insertion mutation: a report of two cases.
Luo Q, Chen L, Li Z, Cheng L, Zhang S, Zong Y, Li Q, Suda K, Santarpia M, Dalia S, Meng R. Luo Q, et al. Among authors: suda k. Transl Lung Cancer Res. 2023 Nov 30;12(11):2330-2341. doi: 10.21037/tlcr-23-542. Epub 2023 Nov 20. Transl Lung Cancer Res. 2023. PMID: 38090524 Free PMC article.
Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing.
Koga T, Soh J, Hamada A, Miyano Y, Fujino T, Obata K, Ohara S, Nishino M, Chiba M, Shimoji M, Takemoto T, Suda K, Sakai K, Sato H, Mitsudomi T. Koga T, et al. Among authors: suda k. JTO Clin Res Rep. 2023 Jul 27;4(9):100554. doi: 10.1016/j.jtocrr.2023.100554. eCollection 2023 Sep. JTO Clin Res Rep. 2023. PMID: 37681218 Free PMC article.
Prognostic role of preoperative fluorine-18 fluorodeoxyglucose-positron emission tomography/computed tomography with an image-based harmonization technique: A multicenter retrospective study.
Hamada A, Kitajima K, Suda K, Koga T, Soh J, Kaida H, Ito K, Sekine T, Takegahara K, Daisaki H, Hashimoto M, Yoshida Y, Kabasawa T, Yamasaki T, Hirota S, Usuda J, Ishii K, Mitsudomi T. Hamada A, et al. Among authors: suda k. JTCVS Open. 2023 Feb 14;14:502-522. doi: 10.1016/j.xjon.2023.02.004. eCollection 2023 Jun. JTCVS Open. 2023. PMID: 37425462 Free PMC article.
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Yoshimura A, Yamada T, Serizawa M, Uehara H, Tanimura K, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Shukuya T, Nishiyama A, Goto Y, Shiotsu S, Kunimasa K, Morimoto K, Katayama Y, Suda K, Mitsudomi T, Yano S, Kenmotsu H, Takahashi T, Takayama K. Yoshimura A, et al. Among authors: suda k. Cancer Sci. 2023 Feb;114(2):606-618. doi: 10.1111/cas.15608. Epub 2022 Nov 11. Cancer Sci. 2023. PMID: 36169649 Free PMC article.
119 results